Fig. 1: Protective efficacy of R69-4 in multiple mouse models. | Nature Communications

Fig. 1: Protective efficacy of R69-4 in multiple mouse models.

From: A subset of type-II collagen-binding antibodies prevents experimental arthritis by inhibiting FCGR3 signaling in neutrophils

Fig. 1

a R69-4 protected against cartilage antibody-induced arthritis (CAIA) in BQ.Cia9i mice (Two-way ANOVA); cartilage antibody cocktail (Cab4): 4 mg, d0, i.v.; R69-4: 2 mg, d1, i.v.; lipopolysaccharide (LPS) boost: 25 µg, d5, i.p. b R69-4 protected against CAIA in BQ.Fcgr2b- mice (Two-way ANOVA); Cab4: 2 mg, d0, i.v.; R69-4: 1 mg, d1, i.v.. c R69-4 protected against collagen-induced arthritis (CIA) in BQ.Ncf1m1j mice (Two-way ANOVA); rat collagen type II (COL2): 100 µg emulsified in complete Freund’s adjuvant (CFA), d0, i.d.; boost: rat COL2 (50 µg) emulsified in incomplete Freund’s adjuvant (IFA), d21, i.d.; R69-4: 1 mg, d23, i.v.. d R69-4 failed to protect against human GPI325-339 peptide-induced arthritis (GPIA) in BQ.Ncf1m1j mice (Two-way ANOVA); hGPI325-339 peptide: 10 µg emulsified in CFA, d0, i.d.; R69-4: 1 mg, d11, i.v.. e, f R69-4 failed to protect against mannan-induced psoriasis (MIP) or psoriatic arthritis in BQ.Ncf1m1j mice (Two-way ANOVA); mannan: 20 mg, d0, i.p.; R69-4: 1 mg, d1, i.v.. All plots were shown as mean + standard deviation (SD). Placebo: 0.01 M glycine, 0.15 M NaCl in all plots.

Back to article page